Dr Reddy’s Lab shares jumped 4% on June 5, making it the top gainer on the Nifty 50. This surge followed the announcement of a strategic partnership with Alvotech to develop a biosimilar version of Keytruda, a blockbuster cancer drug. The stock closed at Rs 1,303, reflecting strong market confidence in this global collaboration.
But what does this mean for regular folks? Keytruda is an immunotherapy drug that earned $29.5 billion worldwide in 2024. It fights many cancers but comes with a hefty price tag.
By teaming up, Dr Reddy’s Lab and Alvotech aim to create a cheaper biosimilar. This could make life-saving treatments more affordable and accessible for patients everywhere.
The partnership isn’t just a handshake; it’s a full-on joint venture. Both companies will share the costs, handle development, manufacturing, and marketing worldwide—except in a few special cases. This means faster development and a wider reach for the biosimilar. It’s like two superheroes joining forces to fight the high cost of cancer care.
On top of the partnership news, HSBC upgraded Dr Reddy’s Lab stock from ‘Hold’ to ‘Buy’. They also raised the target price to Rs 1,445, up from Rs 1,235.
Also Read Adani Takes Off: $750M Funding Set to Transform Indian Airports…
HSBC highlights another star player for Dr Reddy’s—Semaglutide, a drug for type-2 diabetes.
Semaglutide is expected to boost earnings sharply in key markets like Canada, Brazil, and India. Unlike most generics, its price isn’t expected to drop much soon because demand is still high. So, Dr Reddy’s Lab has multiple growth engines firing at once.
Over the past month, Dr Reddy’s Lab shares gained 9%, beating the Nifty 50’s 1% rise. Investors seem to be betting on this company’s future with good reason.
Here’s a little irony: Big pharma often faces criticism for high prices, but biosimilars like the one Dr Reddy’s is co-developing could be a game-changer. It’s like buying a fancy coffee at half the price—same quality, less wallet pain.
Disclaimer:
This article is for informational purposes only and does not constitute investment advice. Please consult a certified financial advisor before making any investment decisions.
Also Read What Do HAL, L&T, and a ₹1.7 Lakh Crore Pipeline Have in Common? Jefferies Just Spilled It
